Myriad Genetics, Inc.

Myriad Genetics, Inc.

Myriad Genetics, Inc.

Overview
Date Founded

1992

Headquarters

320 WAKARA WAY, SALT LAKE CITY, UT, 84108

Type of Company

Public

Employees (Worldwide)

2,700

Industries

Medical Products & Equipment
Pharmaceuticals
Biotechnology

Company Description

Our goal, at Myriad, is to make a difference in patient’s lives and for the past twenty years, the Company’s strategy has been guided by this mission. To accomplish this, we are focused on revolutionizing patient care through the development and marketing of transformative tests which address pressing clinical needs across multiple medical specialties. Over the last twenty years, Myriad has invested heavily in the education of patients and health care providers on the role genes and their related proteins play in disease. Almost one million patients have already benefited from Myriad’s informative testing, which helps physicians better manage their health care. Today, Myriad continues to build on this strong tradition. We are working to expand our reach by introducing new genetic tests and molecular diagnostic tests for a number of diseases. We also are focused on extending our mission internationally, in an effort to broaden our geographic footprint and provide critical information to more patients and healthcare providers

Contact Data
Trying to get in touch with decision makers at Myriad Genetics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer, Treasurer & Executive Vice President

Executive Vice President, General Counsel & Secretary

Chief Technology Officer

Chief Scientific Officer

Group President, Myriad Oncology, Myriad Women's Health & Myriad International

President, Myriad RBM

President, Myriad Autoimmune & Crescendo Bioscience, Inc

President-Myriad Neuroscience

Executive Vice President, Strategy & Innovation

Board of Directors

Former Senior Vice President, Chief Accounting Officer, Controller & Chief Financial Officer at Anthem, Inc.

Founder at Avid Radiopharmaceuticals, Inc.

Former Executive Vice President & Chief Operating Officer at Health Care Service Corp.

Strategic Advisor at Oncology Analytics, Inc.

Co-Founder at Rapidscan Pharma Solutions, Inc.

Clinical Professor, Department of Psychiatry at Georgetown University - School of Medicine

Chief Information Officer & Senior Vice President at Hewlett-Packard Enterprise Co.

Venture Partner, Biotechnology at SV Health Investors LLP

Paths to Myriad Genetics, Inc.
Potential Connections via
Relationship Science
You
Myriad Genetics, Inc.
Owners & Shareholders
Details Hidden

EARNEST Partners is an institutional investment firm with a global network that we believe enables us to see and to seize opportunities that other investors overlook or cannot access. The firm manages approximately $20 billion in assets for clients around the world, including corporate pension plans, state and municipal pension plans, jointly-trusteed plans, foundations, endowments and sovereign wealth funds. We also manage portfolios for high net worth individuals through the platforms of some of the largest broker dealers in the world. In addition to our separate account business, EARNEST Partners is the sole subadvisor for the Hancock Horizon Diversified International Fund, the Touchstone Total Return Bond Fund and the Harbor Small Cap Value Fund. The Firm manages Approximately $20 Billion in assets for clients around the world. Local Touch We are fundamental, bottom-up investors; our investment decisions focus on the merits of individual securities. We believe the best investment decisions are thoughtfully distilled from a pool of expertise, and we are pleased to offer our clients a team with the experience and the network to assess the relevant geopolitical issues, demographic trends and cultural considerations impacting our investments. As a component of our due diligence process, investment team members regularly perform company visits across the Americas, the Asia Pacific region, Western and Eastern Europe, the Middle East and the Sub-continent. Collectively, EARNEST Partners' stakeholders have lived and worked in dozens of countries, and are fluent in the language, commerce and culture of diverse economies that represent a significant portion of the world's economic value and future growth. We believe that identifying the most attractive investment opportunities takes the proper focus: a global focus.

Details Hidden

Camber Capital Management seeks to generate capital appreciation without regard to current income by investing primarily in publicly-traded common stocks of healthcare companies across a variety of industries including healthcare services and facilities, pharmaceuticals, medical products and devices and biotechnology. Although most of their investments are within the healthcare industry, the firm may occasionally invest in other sectors if more attractive opportunities are identified. Camber Capital Management employs a fundamental, bottom-up research approach designed to identify high-quality companies whose inherent value is not adequately reflected in a company's market valuation.

Details Hidden

Glenview's investment process employs deep, fundamental research and individual security selection primarily within equity and credit-oriented strategies. The firm employs a GARP investment approach that focuses on companies in stable industries, with recurring revenue streams or entrenched market positions. They may also focus on contrarian investments (cyclical or company specific). Glenview often combines GARP and contrarian investing when a steady growth business emerges within a company as the dominant economic force over a more challenged business unit. GCM invests in stored or hidden value situations, where excess balance sheet capacity may be used to accelerate returns or where contractual rights or startup operations show no present value but may be significant drivers of value tomorrow. In addition to long equity investments, GCM commits significant capital to short equity positions. They look for companies whose industries face cyclical, transitory or secular headwinds, whose competitive position is likely to erode over the near- to medium-term, and companies whose liquidity profile will potentially create equity value impairment or cause future issuance of additional equity at lower prices. GCM may also maintain short positions in equity index futures or other index products to reduce net market risk. The firm also engages in long and short credit positions with emphasis on business or asset stability over growth. They may seek to reduce the risk through other hedges that protect the overall portfolio of the funds, including interest rates, foreign currencies or sovereign, corporate or asset-backed credit spreads.

Recent Transactions
Details Hidden

Myriad Genetics, Inc. purchases Counsyl, Inc. from WP Global Partners LLC, The Founders Fund Management LLC, Felicis Ventures Management Co. LLC, NB Alternatives Advisers LLC, The Gramercy Fund LLC, Aarin Capital Partners, Pilot Growth Management LLC, Perceptive Advisors (Private Equity)

Details Hidden

Myriad Genetics, Inc. purchases Assurex Health, Inc. from Blue Chip Venture Co, Sequoia Capital, Mayo Medical Ventures, Claremont Creek Ventures, CincyTech LLC, Queen City Angels, North Coast Ventures, Rev1 Ventures, Allos Ventures LLC

Details Hidden

Myriad Genetics, Inc. purchases Myriad International GmbH from Intelligent Venture Capital Management GmbH, Creathor Venture Management GmbH

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onMyriad Genetics, Inc. issued USD Common Stock

Legal Advisor

Advised onMyriad Genetics, Inc. purchases Assurex Health, Inc. from Blue Chip Venture Co, Sequoia Capital, Mayo Medical Ventures, Claremont Creek Ventures, CincyTech LLC, Queen City Angels, North Coast Ventures, Rev1 Ventures, Allos Ventures LLC

Investment Advisor

Advised onMyriad Genetics, Inc. purchases Crescendo Bioscience, Inc. from Safeguard Scientifics, Inc., Kleiner Perkins Caufield & Byers LLC, Skyline Management LLC, Mohr Davidow Ventures, Calibrium Private Investments GmbH

Chair of the Securities Practice Group

Advised onMyriad Genetics, Inc. purchases Crescendo Bioscience, Inc. from Safeguard Scientifics, Inc., Kleiner Perkins Caufield & Byers LLC, Skyline Management LLC, Mohr Davidow Ventures, Calibrium Private Investments GmbH

Legal Advisor

Advised onMyriad Genetics, Inc. purchases Crescendo Bioscience, Inc. from Safeguard Scientifics, Inc., Kleiner Perkins Caufield & Byers LLC, Skyline Management LLC, Mohr Davidow Ventures, Calibrium Private Investments GmbH

Counsel

Advised onMyriad Genetics, Inc. purchases Myriad International GmbH from Intelligent Venture Capital Management GmbH, Creathor Venture Management GmbH

Advisors & Consultants
Legal Advisor

Co-Chair, Intellectual Property Practice at Jones Day

Legal Advisor

Advisor at Pod Investment

Legal Advisor

Former Founding Partner at Cooley LLP

Clients

Progyny, Inc. is a fertility benefits management company, which provides fertility and pharmacy benefits solutions to employers, managing IUI, IVF, egg freezing and other fertility treatments. Its benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA) and provides access to a premier network of fertility specialists using the latest science and technology. The company was founded on April 03, 2008 and is headquartered in New York, NY.

The Government of the United States of America is the federal government of the republic of fifty states that constitute the United States, as well as one capital district, and several other territories. The federal government is composed of three distinct branches: legislative, executive and judicial, whose powers are vested by the U.S. Constitution in the Congress, the President, and the federal courts, including the Supreme Court, respectively.

Key Stats and Financials As of 2020
Market Capitalization
$2.17B
Total Enterprise Value
$920M
Earnings Per Share
$-2.69
Revenue
$639M
EBITDAMargin
-9.83%
Enterprise Value / Sales
1.44x
EBITDA
$-62.8M
Total Equity
$918M
Total Debt
$295M
Net Profit
$-200M
TEVNet Income
-4.61x
Debt TEV
0.32x
Three Year Compounded Annual Growth Rate Of Revenue
-6.1%
Non-Profit Donations & Grants
$50K - $100K
2019
$10K - $25K
2018
$5,000 - $10K
2018
Investments
Details Hidden

RainDance Technologies, Inc. engages in the development and commercialization of professional laboratory system. It develops and manufactures genomic tools for non-invasive liquid biopsy applications for the research, early detection, treatment of cancer, and inherited and infectious diseases. The company was founded by Andrew Griffiths, Darren R. Link, and Jerome Bibette in 2004 and is headquartered in Billerica, MA.

Details Hidden

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest.The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include:a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity,b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade andc) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation.

Details Hidden

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform.Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome).Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process.Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies.Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry.

Investors
Details Hidden

Partner at Great Oaks Venture Capital BZ LLC

Details Hidden

Founder at Felicis Ventures Management Co. LLC

Details Hidden

Chief Operating Officer at ForAllSecure

Suppliers
Oklahoma Medical Research Foundation Social Interest | Oklahoma City, OK

Oklahoma Medical Research Foundation provides investment advice. The company was founded in 1946 and is headquartered in Oklahoma City, OK.

University of Texas - MD Anderson Cancer Center Medical Support Services | Houston, TX

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 68 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s "Best Hospitals" survey has ranked MD Anderson as one of the nation’s top two cancer centers every year since the survey began in 1990.

The Children's Medical Center Corp. Hospitals & Patient Services | Boston, MA

The Children's Medical Center Corp. operates as a non-profit hospital and research center. The company was founded in 1959 and is headquartered in Boston, MA.

Awards & Honors
Rank #33
2012
Forbes Magazine - 50 Best Small Companies 2012
Sponsored by Forbes Media LLC
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Myriad Genetics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Myriad Genetics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Myriad Genetics, Inc..